131 related articles for article (PubMed ID: 11953565)
21. 18F-FDG PET for Measurement of Response and Prediction of Outcome to Relapsed or Refractory Mantle Cell Lymphoma Therapy with Bendamustine-Rituximab.
Lamonica D; Graf DA; Munteanu MC; Czuczman MS
J Nucl Med; 2017 Jan; 58(1):62-68. PubMed ID: 27469362
[TBL] [Abstract][Full Text] [Related]
22. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
23. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
24. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT in a case of bilateral lacrimal gland infiltration by mantle cell lymphoma.
Martínez-Esteve A; García-Gómez FJ; Borrero-Martin JJ; Fajardo-Pico E; Borrego-Dorado I
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):396-7. PubMed ID: 25956958
[No Abstract] [Full Text] [Related]
26. Neurological picture. FDG-PET in meningeal lymphomatosis.
Shinohara M; Kosaka S; Okamura T; Yamamoto T
J Neurol Neurosurg Psychiatry; 2007 Sep; 78(9):974. PubMed ID: 17702776
[No Abstract] [Full Text] [Related]
27. Giant Cell Tumor of the Tendon Sheath With Discordant Metabolism as a False Positive on Staging of Mantle Cell Lymphoma.
Rezaee A; Chen W; Dilsizian V; Chen Q; Kimball AS
Clin Nucl Med; 2015 Oct; 40(10):814-5. PubMed ID: 26053722
[TBL] [Abstract][Full Text] [Related]
28. F-18 FDG PET/CT imaging in recurrent mantle cell lymphoma presenting with cauda equina syndrome.
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Gumus M
Clin Nucl Med; 2010 Mar; 35(3):211-2. PubMed ID: 20173464
[No Abstract] [Full Text] [Related]
29. Detection of incidental colorectal pathology on positron emission tomography/computed tomography.
Mui M; Akhurst T; Warrier SK; Lynch AC; Heriot AG
ANZ J Surg; 2018 Mar; 88(3):E122-E126. PubMed ID: 27580915
[TBL] [Abstract][Full Text] [Related]
30. Potential clinical role of fluorodeoxyglucose-positron emission tomography in assessing primary or secondary lymphomas of the parotid gland.
Basu S; Mahne A; Iruvuri S; Alavi A
Clin Lymphoma Myeloma; 2007 Jan; 7(4):309-14. PubMed ID: 17324340
[TBL] [Abstract][Full Text] [Related]
31. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography in the management of patients with indolent non-Hodgkin's lymphoma.
Naumann R; Beuthien-Baumann B
Clin Lymphoma; 2003 Jun; 4(1):50-1. PubMed ID: 12837155
[No Abstract] [Full Text] [Related]
33. Clinical significance of incidental [18 F]FDG uptake in the gastrointestinal tract on PET/CT imaging: a retrospective cohort study.
Shmidt E; Nehra V; Lowe V; Oxentenko AS
BMC Gastroenterol; 2016 Oct; 16(1):125. PubMed ID: 27716085
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Bailly C; Carlier T; Berriolo-Riedinger A; Casasnovas O; Gyan E; Meignan M; Moreau A; Burroni B; Djaileb L; Gressin R; Devillers A; Lamy T; Thieblemont C; Hermine O; Kraeber-Bodéré F; Le Gouill S; Bodet-Milin C
Haematologica; 2020 Jan; 105(1):e33-e36. PubMed ID: 31371411
[No Abstract] [Full Text] [Related]
35. FDG-PET/CT response assessment with qualitative Lugano criteria outperforms change in SUV
Russler-Germain DA; Calhoun BR; Wu N; Watkins MP; Siegel BA; Bartlett NL; Mhlanga JC
Leuk Lymphoma; 2023; 64(11):1870-1874. PubMed ID: 37489928
[No Abstract] [Full Text] [Related]
36. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
37. F-18 fluorodeoxyglucose positron emission tomography in the non-invasive staging of non-small cell lung cancer.
Berlangieri SU; Scott AM; Knight SR; Fitt GJ; Hennessy OF; Tochon-Danguy HJ; Clarke CP; McKay WJ
Eur J Cardiothorac Surg; 1999 Sep; 16 Suppl 1():S25-30. PubMed ID: 10536941
[TBL] [Abstract][Full Text] [Related]
38. Positron emission tomography in mantle cell lymphoma.
Brepoels L; Stroobants S; De Wever W; Dierickx D; Vandenberghe P; Thomas J; Mortelmans L; Verhoef G; De Wolf-Peeters C
Leuk Lymphoma; 2008 Sep; 49(9):1693-701. PubMed ID: 18798104
[TBL] [Abstract][Full Text] [Related]
39. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
[TBL] [Abstract][Full Text] [Related]
40. A pilot study to evaluate 3'-deoxy-3'-18F-fluorothymidine pet for initial and early response imaging in mantle cell lymphoma.
Herrmann K; Buck AK; Schuster T; Rudelius M; Wester HJ; Graf N; Scheuerer C; Peschel C; Schwaiger M; Dechow T; Keller U
J Nucl Med; 2011 Dec; 52(12):1898-902. PubMed ID: 22065875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
